Exploiting DNA Replication Stress for Cancer Treatment.

Complete and accurate DNA replication is fundamental to cellular proliferation and genome stability. Obstacles that delay, prevent, or terminate DNA replication cause the phenomena termed DNA replication stress. Cancer cells exhibit chronic replication stress due to the loss of proteins that protect or repair stressed replication forks and due to the continuous proliferative signaling, providing an exploitable therapeutic vulnerability in tumors. Here, we outline current and pending therapeutic approaches leveraging tumor-specific replication stress as a target, in addition to the challenges associated with such therapies. We discuss how replication stress modulates the cell-intrinsic innate immune response and highlight the integration of replication stress with immunotherapies. Together, exploiting replication stress for cancer treatment seems to be a promising strategy as it provides a selective means of eliminating tumors, and with continuous advances in our knowledge of the replication stress response and lessons learned from current therapies in use, we are moving toward honing the potential of targeting replication stress in the clinic.

[1]  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.

[2]  A. Bowie,et al.  Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage , 2018, Molecular cell.

[3]  J. Bartek,et al.  High speed of fork progression induces DNA replication stress and genomic instability , 2018, Nature.

[4]  Martin A. M. Reijns,et al.  CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.

[5]  E. Lecona,et al.  Targeting ATR in cancer , 2018, Nature Reviews Cancer.

[6]  D. Sabatini,et al.  Histidine catabolism is a major determinant of methotrexate sensitivity , 2018, Nature.

[7]  A. Lau,et al.  The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression , 2018, Molecular Cancer Therapeutics.

[8]  Zhijian J. Chen,et al.  The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer , 2018, The Journal of experimental medicine.

[9]  S. Boulton,et al.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place. , 2018, Cancer discovery.

[10]  V. Costanzo,et al.  SAMHD1 acts at stalled replication forks to prevent interferon induction , 2018, Nature.

[11]  Michael T. Zimmermann,et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.

[12]  Fang Yang,et al.  Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer , 2018, Neoplasia.

[13]  S. Boulton,et al.  Beyond PARP—POLθ as an anticancer target , 2018, Science.

[14]  T. Halazonetis,et al.  Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress , 2018, Nature.

[15]  J. A. Guerra-Assunção,et al.  Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL , 2017 .

[16]  J. Lukas,et al.  Redox-sensitive alteration of replisome architecture safeguards genome integrity , 2017, Science.

[17]  Yan Liu,et al.  Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. , 2017, Cancer research.

[18]  M. Lawrence,et al.  APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. , 2017, Cancer research.

[19]  K. Cimprich,et al.  The essential kinase ATR: ensuring faithful duplication of a challenging genome , 2017, Nature Reviews Molecular Cell Biology.

[20]  Martin A. M. Reijns,et al.  cGAS surveillance of micronuclei links genome instability to innate immunity , 2017, Nature.

[21]  T. Kunkel,et al.  Eukaryotic DNA Replication Fork. , 2017, Annual review of biochemistry.

[22]  Dennis E Discher,et al.  Mitotic progression following DNA damage enables pattern recognition within micronuclei , 2017, Nature.

[23]  P. Hieter,et al.  Synthetic lethality and cancer , 2017, Nature Reviews Genetics.

[24]  Shuang Liu,et al.  Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. , 2017, Oncology reports.

[25]  O. Inanami,et al.  MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis , 2017, Translational oncology.

[26]  A. Ashworth,et al.  Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells , 2017, British Journal of Cancer.

[27]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[28]  S. Aguirre,et al.  Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion , 2017, mBio.

[29]  T. Helleday,et al.  dUTPase inhibition augments replication defects of 5-Fluorouracil , 2017, Oncotarget.

[30]  E. Wakeland,et al.  RAD51 interconnects between DNA replication, DNA repair and immunity , 2017, Nucleic acids research.

[31]  A. Harris,et al.  A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1 , 2017, Genes & development.

[32]  Eric S. Lander,et al.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.

[33]  Petras Juzenas,et al.  Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading , 2016, Oncotarget.

[34]  S. Jackson,et al.  Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. , 2017, Cancer discovery.

[35]  T. Helleday,et al.  Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities , 2015, Cell reports.

[36]  Mark Morgan,et al.  Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models , 2016, Clinical Cancer Research.

[37]  Samuel E. Jones,et al.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.

[38]  A. Oza,et al.  Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Backos,et al.  Targeting WEE1 Kinase in Cancer. , 2016, Trends in pharmacological sciences.

[40]  Suzanne F. Jones,et al.  Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Galsky,et al.  Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors , 2016, Oncology.

[42]  M. C. Cardoso,et al.  RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA , 2016, Nature Communications.

[43]  M. Lopes,et al.  Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks. , 2016, Cell reports.

[44]  T. Stankovic,et al.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.

[45]  G. Barber,et al.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. , 2016, Cell reports.

[46]  Y. Wu,et al.  ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer , 2015, Oncotarget.

[47]  Emily J. Girard,et al.  Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. , 2015, Cell reports.

[48]  Y. Liu,et al.  Replication stress activates DNA repair synthesis in mitosis , 2015, Nature.

[49]  S. Sarkar,et al.  Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation , 2015, Cancer cell.

[50]  T. Conrads,et al.  The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.

[51]  Jessica L. Boisvert,et al.  Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. , 2015, Molecular cell.

[52]  D. Cortez,et al.  The Replication Checkpoint Prevents Two Types of Fork Collapse without Regulating Replisome Stability. , 2015, Molecular cell.

[53]  D. Jodrell,et al.  CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. , 2015, Cancer research.

[54]  D. Cortez.  Preventing replication fork collapse to maintain genome integrity. , 2015, DNA repair.

[55]  A. Trumpp,et al.  A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer , 2015, Cell.

[56]  M. Méchali,et al.  DNA replication origin activation in space and time , 2015, Nature Reviews Molecular Cell Biology.

[57]  Matthew Meyerson,et al.  CHROMOTHRIPSIS FROM DNA DAMAGE IN MICRONUCLEI , 2015, Nature.

[58]  J. Pietenpol,et al.  A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments , 2015, PloS one.

[59]  K. Ishii,et al.  Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. , 2015, Cell reports.

[60]  P. Jallepalli,et al.  ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress. , 2015, Molecular cell.

[61]  Raquel Herrador,et al.  Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells , 2015, The Journal of cell biology.

[62]  Thanos D Halazonetis,et al.  DNA replication stress as a hallmark of cancer. , 2015, Annual review of pathology.

[63]  Y. Pommier,et al.  ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. , 2014, Cancer research.

[64]  P. Reaper,et al.  Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 , 2014, Oncotarget.

[65]  P. Ménard,et al.  Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components , 2014, Nature Cell Biology.

[66]  N. Mailand,et al.  ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.

[67]  George Iliakis,et al.  Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells , 2014, Science.

[68]  I. Calvo-Asensio,et al.  ATR activates the S-M checkpoint during unperturbed growth to ensure sufficient replication prior to mitotic onset. , 2013, Cell reports.

[69]  M. Gaestel,et al.  Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity , 2013, Proceedings of the National Academy of Sciences.

[70]  N. Bec,et al.  FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling. , 2013, Molecular cell.

[71]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[72]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[73]  B. Kaina,et al.  Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide , 2013, Molecular Cancer Therapeutics.

[74]  Fabien Zoulim,et al.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases , 2013, Nature Reviews Drug Discovery.

[75]  G. Giaever,et al.  DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. , 2013, Chemistry & biology.

[76]  K. Cimprich,et al.  Causes and consequences of replication stress , 2013, Nature Cell Biology.

[77]  S. Patzke,et al.  Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption , 2012, Molecular and Cellular Biology.

[78]  M. Morita,et al.  ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity. , 2012, DNA repair.

[79]  D. Cortez,et al.  Monitoring the spatiotemporal dynamics of proteins at replication forks and in assembled chromatin using isolation of proteins on nascent DNA , 2012, Nature Protocols.

[80]  L. Samson,et al.  Balancing repair and tolerance of DNA damage caused by alkylating agents , 2012, Nature Reviews Cancer.

[81]  Neil J Ganem,et al.  DNA breaks and chromosome pulverization from errors in mitosis , 2012, Nature.

[82]  O. Fernandez-Capetillo,et al.  Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.

[83]  R. Medema,et al.  Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease , 2011, The Journal of cell biology.

[84]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[85]  James R Bischoff,et al.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations , 2011, Nature Structural &Molecular Biology.

[86]  P. C. de Witt Hamer,et al.  WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.

[87]  B. Kerem,et al.  Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development , 2011, Cell.

[88]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[89]  B. Neumann,et al.  53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress , 2011, Nature Cell Biology.

[90]  H. Piwnica-Worms,et al.  Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. , 2011, Trends in molecular medicine.

[91]  Cristina Al-Khalili Szigyarto,et al.  Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate , 2010, Nucleic acids research.

[92]  J. Blow,et al.  Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories , 2010, The Journal of cell biology.

[93]  B. Nabet,et al.  Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. , 2010, Cancer research.

[94]  T. Helleday,et al.  Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair , 2010, Molecular cell.

[95]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[96]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[97]  P. Fernandes,et al.  Understanding ribonucleotide reductase inactivation by gemcitabine. , 2007, Chemistry.

[98]  M. Bataller,et al.  Mitotic catastrophe as a consequence of chemotherapy. , 2006, Anti-cancer agents in medicinal chemistry.

[99]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[100]  M. Pacek,et al.  Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. , 2005, Genes & development.

[101]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[102]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[103]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[104]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[105]  D. Loegering,et al.  The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons* , 2005, Journal of Biological Chemistry.

[106]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[107]  R. Kuchta,et al.  Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. , 2004, Biochemical pharmacology.

[108]  J. Diffley,et al.  Visualization of Altered Replication Dynamics after DNA Damage in Human Cells* , 2004, Journal of Biological Chemistry.

[109]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[110]  D. Gisselsson,et al.  Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[112]  T. Dobzhansky,et al.  Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.

[113]  T. Dobzhansky,et al.  Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. , 1946, Genetics.

[114]  R. Medema,et al.  Wee 1 controls genomic stability during replication by regulating the Mus 81-Eme 1 endonuclease , 2022 .